5.1.3.14 (2S)-2-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanamide - 192421 5.1.3.14 (2S)-2-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid i.e. Epimerox, 2-epimerase inhibition through a target-specific mechanism, in vivo efficacy against Staphylococcus aureus and Bacillus anthracis 192422 5.1.3.14 (2S)-2-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]butanoic acid - 192423 5.1.3.14 (2S)-2-[(4E)-4-[[5-(3,4-dichlorophenyl)thiophen-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192424 5.1.3.14 (2S)-2-[(4E)-4-[[5-(3,5-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192425 5.1.3.14 (2S)-2-[(4E)-4-[[5-(3-chloro-4-methoxyphenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192426 5.1.3.14 (2S)-2-[(4E)-4-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192427 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-bromo-3-chlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192428 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-bromo-3-chlorophenyl)thiophen-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192429 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-bromophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192430 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-bromophenyl)thiophen-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192431 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192432 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-chlorophenyl)thiophen-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192433 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-fluorophenyl)thiophen-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192434 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-iodophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192435 5.1.3.14 (2S)-2-[(4E)-4-[[5-(4-methoxyphenyl)thiophen-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192436 5.1.3.14 (2S)-2-[(4E)-5-oxo-2-thioxo-4-([5-[4-(trifluoromethoxy)phenyl]furan-2-yl]methylidene)imidazolidin-1-yl]-3-phenylpropanoic acid - 192437 5.1.3.14 (2S)-2-[(4E)-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-2-thioxoimidazolidin-1-yl]-3-phenylpropanoic acid - 192438 5.1.3.14 2',3'-dialdehydro-ADP efficient inhibition is most likely due to the structural similarity to o-UDP and not to an allosteric effect via the ATP binding site 118582 5.1.3.14 2',3'-dialdehydro-UDP binds to the active site of the enzyme 118581 5.1.3.14 2',3'-dialdehydro-UDP-alpha-D-N-acetylglucosamine 0.05 mM, 70% inhibition after 30 min. 0.25 mM, 90% inhibition. Covalently bound to amino acids in the active site causing an irreversible inhibition. Effective inhibitor may serve as a basis for the chemical synthesis of further inhibitors 118580 5.1.3.14 2-acetamidoglucal - 227846 5.1.3.14 2-acetamidoglucal recombinant enzyme 227846 5.1.3.14 3-acetamido-2,6-anhydro-3-deoxy-D-arabino-hept-2-enopyranosonate - 118588 5.1.3.14 Ca2+ - 15 5.1.3.14 Ca2+ slight inhibition at 10 mM 15 5.1.3.14 Cd2+ - 52 5.1.3.14 CMP-N-acetylneuraminic acid - 4513 5.1.3.14 CMP-N-acetylneuraminic acid 50% inhibition by 0.025 mM 4513 5.1.3.14 CMP-N-acetylneuraminic acid feedback inhibitor 4513 5.1.3.14 CMP-Neu5Ac allosterical feed-back-inhibition 2449 5.1.3.14 CMP-Neu5Ac feedback inhibition 2449 5.1.3.14 CMP-sialic acid GNE/MNK is feedback inhibited by binding of the downstream product, CMP-sialic acid, in its allosteric site. The allosteric regulation by CMP-sialic acid involves residues D255, E260, R263, R266, K268, and N275 78295 5.1.3.14 Co2+ - 23 5.1.3.14 Co2+ strong inhibition at 10 mM 23 5.1.3.14 Cs+ - 580 5.1.3.14 Cu2+ - 19 5.1.3.14 Cu2+ slight inhibition at 10 mM 19 5.1.3.14 ethyl (2S)-2-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoate - 193224 5.1.3.14 ethyl (2S)-2-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-3-phenylpropanoates - 194465 5.1.3.14 Fe3+ - 70 5.1.3.14 Hg2+ - 33 5.1.3.14 Li+ - 152 5.1.3.14 Mg2+ - 6 5.1.3.14 Mg2+ slight inhibition at 10 mM 6 5.1.3.14 Mn2+ - 11 5.1.3.14 Mn2+ complete inhibition at 10 mM, the epimerase and the activity cannot be rescued by subsequent addition of EDTA 11 5.1.3.14 Mn2+ leads to enzyme precipitation at 10 mM 11 5.1.3.14 additional information UDP-glycal derivatives as transition state analogues of GNE substrates are synthesized, especially UDP-exo-glycal derivatives, C-glycosidic derivatives of 2-acetamidoglucal, and ketosides as bisubstrate analogues and bis-product analogues, respectively. Derivatives of 1-deoxyiminosugars with and without substitution of the iminogroup in the ring are promising GNE inhibitors, designed as transition-state analogues of the known enzymatic mechanism of UDP-GlcNAc 2-epimerase 2 5.1.3.14 additional information UDP-glycal derivatives as transition state analogues of GNE substrates are synthesized, especially UDP-exo-glycal derivatives, C-glycosidic derivatives of 2-acetamidoglucal, and ketosides as bissubstrate analogues and bis-product analogues, respectively. Derivatives of 1-deoxyiminosugars with and without substitution of the iminogroup in the ring are promising GNE inhibitors, designed as transition-state analogues of the known enzymatic mechanism of UDP-GlcNAc 2-epimerase 2 5.1.3.14 additional information synthesis and evaluation of specific inhibitors, overview 2 5.1.3.14 additional information both 2-acetamidoglucal and UDP show competitive inhibitory effects for the UDP-ManNAc 2-epimerization of NmSacA-His6. No inhibition by EDTA, and 1 mM DTT 2 5.1.3.14 additional information WTA 2-epimerases are dual beta-lactam potentiation and antibiofilm drug targets; WTA 2-epimerases are dual beta-lactam potentiation and antibiofilm drug targets 2 5.1.3.14 additional information WTA 2-epimerases are dual beta-lactam potentiation and antibiofilm drug targets 2 5.1.3.14 N-[1-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-2-phenylethyl]-1,1,1-trifluoromethanesulfonamide - 193351 5.1.3.14 N-[1-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-2-phenylethyl]methanesulfonamide - 193352 5.1.3.14 N-[1-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]propyl]methanesulfonamide - 193353 5.1.3.14 NEM - 89 5.1.3.14 Ni2+ - 38 5.1.3.14 Ni2+ slight inhibition at 10 mM 38 5.1.3.14 Pb2+ - 139 5.1.3.14 PCMB - 78 5.1.3.14 Selenite - 1937 5.1.3.14 SeO2 - 98244 5.1.3.14 tunicamycin the natural product antibiotic physically binds Cap5P and inhibits 2-epimerase activity, NMR study, reversible inhibition; the natural product antibiotic physically binds MnaA and inhibits 2-epimerase activity, NMR study, reversible inhibition 1659 5.1.3.14 tunicamycin the natural product antibiotic physically binds MnaA and inhibits 2-epimerase activity, NMR study, reversible inhibition 1659 5.1.3.14 UDP - 26 5.1.3.14 UDP competitive 26 5.1.3.14 UDP competitive inhibition 26 5.1.3.14 UDP recombinant enzyme 26 5.1.3.14 UDP binding structure, overview 26 5.1.3.14 UDPglucose - 186 5.1.3.14 UMP - 133 5.1.3.14 uridine 5'-(3-acetamido-3-deoxy-2-O-methyl-alpha-D-gluco-hept-2-ulopyranos-1-yl diphosphate) - 118589 5.1.3.14 uridine 5'-(3-acetamido-3-deoxy-2-O-methyl-alpha-D-manno-hept-2-ulopyranos-1-yl diphosphate) weak 118590 5.1.3.14 uridine 5'-[(Z)-2,6-anhydro-1-deoxy-D-galactohept-1-enitol-1-yl phosphono] phosphate weak 118585 5.1.3.14 uridine 5'-[(Z)-2,6-anhydro-1-deoxy-D-glucohept-1-enitol-1-yl phosphono] phosphate - 118583 5.1.3.14 uridine 5'-[(Z)-2,6-anhydro-1-deoxy-D-mannohept-1-enitol-1-yl phosphono] phosphate - 118584 5.1.3.14 uridine 5'-[(Z)-3-acetamido-2,6-anhydro-1,3-dideoxy-D-arabino-hept-1-enitol-1-yl phosphono] phosphate - 118587 5.1.3.14 uridine 5'-[(Z)-3-acetamido-2,6-anhydro-1,3-dideoxy-D-gluco-hept-1-enitol-1-yl phosphono] phosphate - 118586 5.1.3.14 UTP - 65 5.1.3.14 VO3- - 12727 5.1.3.14 Zn2+ - 14 5.1.3.14 Zn2+ complete inhibition at 10 mM, the epimerase and the activity cannot be rescued by subsequent addition of EDTA 14 5.1.3.14 Zn2+ leads to enzyme precipitation at 10 mM 14 5.1.3.14 [1-[(4E)-4-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-5-oxo-2-thioxoimidazolidin-1-yl]-2-phenylethyl]cyanamide - 193385